These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31658067)

  • 41. Managing the effect of TRIPS on availability of priority vaccines.
    Milstien J; Kaddar M
    Bull World Health Organ; 2006 May; 84(5):360-5. PubMed ID: 16710544
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Learning from practice: compulsory licensing cases and access to medicines.
    Stirner B; Thangaraj H
    Pharm Pat Anal; 2013 Mar; 2(2):195-213. PubMed ID: 24237026
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The impact of the legal regime of intellectual property protection in the pharmaceutical market.
    Pashkov VM; Golovanova IA; Olefir AA
    Wiad Lek; 2016; 69(3 pt 2):582-586. PubMed ID: 27717949
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union:
    't Hoen EFM; Boulet P; Baker BK
    J Pharm Policy Pract; 2017; 10():19. PubMed ID: 28670455
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Alternatives to the drug research and development model.
    Velásquez G
    Salud Colect; 2015 Mar; 11(1):23-34. PubMed ID: 25853828
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Compulsory licensing of patents in India.
    Chaudhry R
    Pharm Pat Anal; 2016 Sep; 5(6):401-406. PubMed ID: 27805847
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Conflicts of interest in research involving human beings.
    Greco D; Diniz NM
    J Int Bioethique; 2008; 19(1-2):143-54, 202-3. PubMed ID: 18664007
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime.
    Halliburton M
    Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158
    [TBL] [Abstract][Full Text] [Related]  

  • 49. TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines.
    Mermelstein S; Stevens H
    Pharmaceutics; 2021 Dec; 14(1):. PubMed ID: 35056944
    [TBL] [Abstract][Full Text] [Related]  

  • 50. COMPULSORY LICENSING IN CONTEXT OF THE COVID-19 PANDEMIC AS A TOOL FOR ENSURING THE BALANCE BETWEEN RIGHTS-HOLDERS' AND SOCIETY'S INTERESTS.
    Chepys O
    Georgian Med News; 2020 Nov; (308):160-165. PubMed ID: 33395660
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug prices and trends before and after requesting compulsory licenses: the Ecuadorian experience.
    Ortiz-Prado E; Cevallos-Sierra G; Teran E; Vasconez E; Borrero-Maldonado D; Ponce Zea J; Simbaña-Rivera K; Gómez-Barreno L
    Expert Opin Ther Pat; 2019 Aug; 29(8):653-662. PubMed ID: 31298053
    [No Abstract]   [Full Text] [Related]  

  • 52. Product patents and access to innovative medicines.
    Dai R; Watal J
    Soc Sci Med; 2021 Dec; 291():114479. PubMed ID: 34700119
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Will the Modi government succumb to US and industry pressure to modify its pro-access pharmaceutical patent policy?
    Baker BK
    Expert Opin Ther Pat; 2015 Jun; 25(6):625-8. PubMed ID: 25704359
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?
    Assefa Y; Hill PS; Ulikpan A; Williams OD
    Global Health; 2017 Sep; 13(1):73. PubMed ID: 28903757
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Access to essential medicines for sexual and reproductive health care: the role of the pharmaceutical industry and international regulation.
    Cottingham J; Berer M
    Reprod Health Matters; 2011 Nov; 19(38):69-84. PubMed ID: 22118143
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug policy and administration affecting quality of life of the poor in Thailand.
    Prutipinyo C; Sirichotiratana N
    Med Law; 2011 Sep; 30(3):311-22. PubMed ID: 22191322
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Divergence and Convergence of Royalty Determinations between Compulsory Licensing under the TRIPS Agreement and Ongoing Royalties as an Equitable Remedy.
    Shore D
    Am J Law Med; 2020 Mar; 46(1):55-88. PubMed ID: 32460655
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An exploration of compulsory licensing as an effective policy tool for antiretroviral drugs in India.
    Jain D; Darrow JJ
    Health Matrix Clevel; 2013; 23(2):425-57. PubMed ID: 24341078
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ownership of knowledge--the role of patents in pharmaceutical R&D.
    Correa CM
    Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intellectual property rights, compulsory licensing and the TRIPS agreement: some ethical issues.
    Schuklenk U
    Monash Bioeth Rev; 2003 Apr; 22(2):63-8. PubMed ID: 15069958
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.